204 related articles for article (PubMed ID: 22663293)
21. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
[TBL] [Abstract][Full Text] [Related]
22. Comparative Clinical Effectiveness Research Focused on Community-Based Delivery of Palliative Care: Overview of the Patient-Centered Outcomes Research Institute's Funding Initiative.
Khan CP; Parver S; Kennedy Lesch J; DiGioia K; Gaglio B; Daugherty S; Clauser SB; Arora NK
J Palliat Med; 2019 Sep; 22(S1):2-6. PubMed ID: 31486731
[TBL] [Abstract][Full Text] [Related]
23. Social welfare and the Affordable Care Act: is it ever optimal to set aside comparative cost?
Mortimer D; Peacock S
Soc Sci Med; 2012 Oct; 75(7):1156-62. PubMed ID: 22739260
[TBL] [Abstract][Full Text] [Related]
24. Investigation of comparative effectiveness research in Asia, Europe, and North America.
Patel I; Rarus R; Tan X; Lee EK; Guy J; Ahmad A; Chang J
Indian J Pharmacol; 2015; 47(6):585-93. PubMed ID: 26729947
[TBL] [Abstract][Full Text] [Related]
25. Opportunities for Patient-centered Outcomes Research in Radiology.
Zygmont ME; Lam DL; Nowitzki KM; Burton KR; Lenchik L; McArthur TA; Sekhar AK; Itri JN
Acad Radiol; 2016 Jan; 23(1):8-17. PubMed ID: 26683507
[TBL] [Abstract][Full Text] [Related]
26. Digital interventions in mental health: evidence syntheses and economic modelling.
Gega L; Jankovic D; Saramago P; Marshall D; Dawson S; Brabyn S; Nikolaidis GF; Melton H; Churchill R; Bojke L
Health Technol Assess; 2022 Jan; 26(1):1-182. PubMed ID: 35048909
[TBL] [Abstract][Full Text] [Related]
27. A CTSA agenda to advance methods for comparative effectiveness research.
Helfand M; Tunis S; Whitlock EP; Pauker SG; Basu A; Chilingerian J; Harrell FE; Meltzer DO; Montori VM; Shepard DS; Kent DM;
Clin Transl Sci; 2011 Jun; 4(3):188-98. PubMed ID: 21707950
[TBL] [Abstract][Full Text] [Related]
28. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(18):1-63. PubMed ID: 23074488
[TBL] [Abstract][Full Text] [Related]
29. Closing the information gap: informing better medical decisionmaking through the use of post-market safety and comparative effectiveness information.
Fox B
Food Drug Law J; 2012; 67(1):83-101, iii. PubMed ID: 24624650
[TBL] [Abstract][Full Text] [Related]
30. Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.
Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
Pain Physician; 2010; 13(1):E23-54. PubMed ID: 20119474
[TBL] [Abstract][Full Text] [Related]
31. Leveraging observational registries to inform comparative effectiveness research.
Shah BR; Drozda J; Peterson ED
Am Heart J; 2010 Jul; 160(1):8-15. PubMed ID: 20598966
[TBL] [Abstract][Full Text] [Related]
32. Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding?
Gandjour A
Pharmacoeconomics; 2011 Jul; 29(7):555-61. PubMed ID: 21534639
[TBL] [Abstract][Full Text] [Related]
33. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
34. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
35. US payer perspectives on evidence for formulary decision making.
Wang A; Halbert RJ; Baerwaldt T; Nordyke RJ
Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP71-6. PubMed ID: 22693984
[TBL] [Abstract][Full Text] [Related]
36. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
37. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research.
Chalkidou K; Tunis S; Whicher D; Fowler R; Zwarenstein M
Clin Trials; 2012 Aug; 9(4):436-46. PubMed ID: 22752634
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness research as choice architecture: the behavioral law and economics solution to the health care cost crisis.
Korobkin R
Mich Law Rev; 2014 Feb; 112(4):523-74. PubMed ID: 24446572
[TBL] [Abstract][Full Text] [Related]
39. Cost, coverage, and comparative effectiveness research: the critical issues for oncology.
Pearson SD
J Clin Oncol; 2012 Dec; 30(34):4275-81. PubMed ID: 23071229
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
